|
Market Closed -
Nasdaq
23:00:00 19/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 21.74 USD | +1.87% |
|
+8.81% | -18.82% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPHASTAR PHARMACEUTICALS, INC. | Other Pharmaceuticals | +1.87% | +8.81% | -18.82% | -28.32% | +16.38% | 925M |  |  |  |
- Stock Market
- Stocks
- AMPH Stock
- Charts Amphastar Pharmaceuticals, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
